NO20032511L - Farmasöytiske sammensetninger for oral tilförsel av farmakologisk aktive midler - Google Patents

Farmasöytiske sammensetninger for oral tilförsel av farmakologisk aktive midler

Info

Publication number: NO20032511L
Authority: NO; Norway
Prior art keywords: pharmacologically active; active agents; pharmaceutical compositions; oral administration; agent
Prior art date: 2000-12-06

Application number

NO20032511A

Other languages

English (en)

Other versions

NO332936B1 (no

NO20032511D0 (no

Inventor

Joseph M Ault

Moise Azria

Simon David Bateman

Joseph Sikora

Gregory Sparta

Rebecca Fai-Ying Yang

Jie Xiao

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-06

Filing date

2003-06-03

Publication date

2003-06-03

2003-06-03 Application filed by Novartis Ag filed Critical Novartis Ag

2003-06-03 Publication of NO20032511L publication Critical patent/NO20032511L/no

2003-06-03 Publication of NO20032511D0 publication Critical patent/NO20032511D0/no

2013-02-04 Publication of NO332936B1 publication Critical patent/NO332936B1/no

Links

239000013543 active substance Substances 0.000 title abstract 5
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 2
102000055006 Calcitonin Human genes 0.000 abstract 1
108060001064 Calcitonin Proteins 0.000 abstract 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
229960004015 calcitonin Drugs 0.000 abstract 1
229960000913 crospovidone Drugs 0.000 abstract 1
229940124447 delivery agent Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
229940069328 povidone Drugs 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Obesity (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20032511A 2000-12-06 2003-06-03 Faste, farmasoytiske sammensetninger for oral tilforsel av kalsitonin NO332936B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25172900P	2000-12-06	2000-12-06
PCT/EP2001/014294 WO2002045754A2 (en)	2000-12-06	2001-12-05	Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Publications (3)

Publication Number	Publication Date
NO20032511L true NO20032511L (no)	2003-06-03
NO20032511D0 NO20032511D0 (no)	2003-06-03
NO332936B1 NO332936B1 (no)	2013-02-04

Family

ID=22953160

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20032511A NO332936B1 (no)	2000-12-06	2003-06-03	Faste, farmasoytiske sammensetninger for oral tilforsel av kalsitonin

Country Status (26)

Country	Link
US (1)	US7049283B2 (no)
EP (1)	EP1341526B1 (no)
JP (2)	JP4898078B2 (no)
KR (1)	KR100847695B1 (no)
CN (1)	CN1304048C (no)
AT (1)	ATE513541T1 (no)
AU (2)	AU2002234547B2 (no)
BR (2)	BR0115965A (no)
CA (1)	CA2436599C (no)
CY (1)	CY1112562T1 (no)
CZ (1)	CZ305418B6 (no)
DK (1)	DK1341526T3 (no)
EC (1)	ECSP034639A (no)
ES (1)	ES2367009T3 (no)
HU (1)	HU230632B1 (no)
IL (2)	IL155992A0 (no)
MX (1)	MXPA03005096A (no)
NO (1)	NO332936B1 (no)
NZ (1)	NZ526196A (no)
PL (1)	PL209703B1 (no)
PT (1)	PT1341526E (no)
RU (1)	RU2287999C2 (no)
SI (1)	SI1341526T1 (no)
SK (1)	SK287613B6 (no)
WO (1)	WO2002045754A2 (no)
ZA (1)	ZA200304295B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1175390B1 (en) *	1999-04-05	2005-02-02	Emisphere Technologies, Inc.	Disodium salts, monohydrates, and ethanol solvates
PL211976B1 (pl) *	2001-06-01	2012-07-31	Novartis Ag	Kompozycja farmaceutyczna do podawania doustnego oraz zastosowanie kompozycji
US20050054557A1 (en) *	2002-05-09	2005-03-10	Goldberg Michael M.	Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) *	2002-07-17	2004-03-01	Novartis Ag	Use of organic compounds
PE20040724A1 (es)	2002-08-01	2004-12-06	Novartis Ag	Composicion para la administracion oral de calcitonina
MXPA05009848A (es) *	2003-03-17	2005-12-06	Japan Tobacco Inc	Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo.
TWI494102B (zh) *	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
ES2330638T3 (es) *	2003-07-11	2009-12-14	Novartis Ag	Composiciones farmaceuticas dosificadas en forma oral que contienen un agente de suministro en forma micronizada.
MXPA06000807A (es) *	2003-07-23	2006-08-23	Novartis Ag	Uso de calcitonina en osteoartritis.
ES2655435T3 (es) *	2003-09-12	2018-02-20	Amgen Inc.	Formulación de disolución rápida de cinacalcet
CN1968704B (zh) *	2004-05-19	2010-12-08	爱密斯菲尔科技公司	局部用色甘酸制剂
GB0422644D0 (en) *	2004-10-12	2004-11-10	Novartis Ag	Organic compounds
GB0427603D0 (en) *	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
ES2540929T3 (es) *	2005-02-01	2015-07-14	Emisphere Technologies, Inc.	Sistema de administración de retención gástrica y liberación controlada
US8030271B2 (en) *	2005-07-05	2011-10-04	Emisphere Technologies, Inc.	Compositions and methods for buccal delivery of human growth hormone
PE20100241A1 (es)	2005-09-19	2010-04-16	Emisphere Tech Inc	Formas cristalinas de la sal di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
GB0522566D0 (en) *	2005-11-04	2005-12-14	Novartis Ag	Organic compounds
RU2469709C2 (ru) *	2005-11-17	2012-12-20	Новартис Аг	Фармацевтическая композиция
JP2009527504A (ja) *	2006-02-23	2009-07-30	イオメディックススリープインターナショナルエスアールエル	良質な睡眠の誘導および維持のための組成物および方法
WO2008021088A2 (en) *	2006-08-08	2008-02-21	The Regents Of The University Of Californina	Salicylanilides enhance oral delivery of therapeutic peptides
AU2007289344B2 (en) *	2006-08-31	2011-04-14	Novartis Ag	Pharmaceutical compositions comprising hGH for oral delivery
CA2572004A1 (en) *	2006-12-08	2008-06-08	Bernard Charles Sherman	Tablets comprising entacapone and crospovidone
KR20150091536A (ko) *	2007-03-02	2015-08-11	노파르티스 아게	칼시토닌의 경구 투여
NZ585080A (en)	2007-11-02	2012-05-25	Emisphere Tech Inc	Composition comprising Vitamin B12 and N-[8-(2-hydroxybenzoyl) amino ]caprylic acid and salts thereof for treating Vitamin B12 deficiency
RU2494755C2 (ru)	2008-08-18	2013-10-10	Интера Био Лтд.	Способы и композиции для перорального введения белков
RU2537181C2 (ru) *	2009-03-12	2014-12-27	Нордик Байосайенс А/С	Лечение диабета и метаболического синдрома
CN103025327A (zh) *	2010-06-09	2013-04-03	艾米斯菲尔技术公司	口服缺铁疗法
MX377589B (es)	2010-12-16	2025-03-10	Novo Nordisk As	Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
RU2602601C2 (ru)	2011-04-12	2016-11-20	Ново Нордиск А/С	Дважды ацилированные производные glp-1
DK2827845T3 (en)	2012-03-22	2019-04-01	Novo Nordisk As	COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN104203266B (zh)	2012-03-22	2017-12-26	诺和诺德股份有限公司	Glp‑1肽组合物及其制备
EP3542790B1 (en)	2012-03-22	2023-09-13	Novo Nordisk A/S	Compositions comprising a delivery agent and preparation thereof
JP6517690B2 (ja)	2012-06-20	2019-05-22	ノヴォノルディスクアー／エス	ペプチド及び送達剤を含む錠剤製剤
JP6672140B2 (ja)	2013-05-02	2020-03-25	ノヴォノルディスクアー／エス	Ｇｌｐ−１化合物の経口投薬
CN104961687B (zh) *	2015-06-03	2017-07-25	苏州维泰生物技术有限公司	1,2‑二嗪衍生物及其制剂、用途
PT3265443T (pt) *	2015-07-08	2020-02-14	Korea Res Inst Chemical Tech	Derivados de pirrolidina carboxamido e métodos de preparação e utilização dos mesmos
WO2017064538A1 (en) *	2015-10-16	2017-04-20	Nobel Ilac Sanayii Ve Ticaret A.S.	Pharmaceutical compositions of nilotinib hydrochloride
CN107080739A (zh) *	2017-04-17	2017-08-22	深圳市泛谷药业股份有限公司	一种用于口服给药的固体快速释放布南色林片及其制备方法
PL3746111T3 (pl)	2018-02-02	2024-01-15	Novo Nordisk A/S	Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
JP2021054781A (ja) *	2019-09-26	2021-04-08	デボンエルエス，リミテッド	共結晶形エフィナコナゾール、及びその製造方法
KR102301743B1 (ko) *	2020-12-29	2021-09-13	대봉엘에스 주식회사	에피나코나졸 경구용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5015633A (en)	1987-04-27	1991-05-14	E. R. Squibb & Sons, Inc.	Method for inhibiting loss of cognitive functions employing an ace inhibitor
US5756450A (en)	1987-09-15	1998-05-26	Novartis Corporation	Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5002771A (en)	1989-02-06	1991-03-26	Rorer Pharmaceutical Corp.	Calcitonin suppository formulations
IT1238072B (it)	1990-01-19	1993-07-03	Sclavo Spa	Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
JPH052771A (ja) *	1991-06-25	1993-01-08	Pioneer Electron Corp	光記録媒体
US5681811A (en)	1993-05-10	1997-10-28	Protein Delivery, Inc.	Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
WO1996018386A1 (en)	1994-12-14	1996-06-20	Enbalt Trading Limited	Pharmaceutical tablet formulations for direct compression
BR9604880A (pt) *	1995-03-31	1998-05-19	Emisphere Tech Inc	Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5866536A (en)	1995-03-31	1999-02-02	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5912014A (en) *	1996-03-15	1999-06-15	Unigene Laboratories, Inc.	Oral salmon calcitonin pharmaceutical products
US5972381A (en)	1996-06-28	1999-10-26	Schering Corporation	Solid solution of an antifungal agent with enhanced bioavailability
EP0839526A3 (en) *	1996-10-31	1999-01-07	Takeda Chemical Industries, Ltd.	Solid pharmaceutical preparation with fast buccal disintegration or dissolution
US5773647A (en)	1997-02-07	1998-06-30	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
CA2319680C (en)	1997-02-07	2010-04-20	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
RO121834B1 (ro)	1998-03-16	2008-06-30	Inhale Therapeutic Systems, Inc.	Dispozitiv pentru administrarea unui agent activ
WO2000057857A1 (en)	1999-03-25	2000-10-05	Yuhan Corporation	Rapidly disintegrable tablet for oral administration
WO2000059480A1 (en) *	1999-04-05	2000-10-12	Emisphere Technologies, Inc.	Lyophilized solid dosage forms and methods of making
EP1175390B1 (en)	1999-04-05	2005-02-02	Emisphere Technologies, Inc.	Disodium salts, monohydrates, and ethanol solvates

2001
- 2001-12-04 US US10/006,311 patent/US7049283B2/en not_active Expired - Fee Related
- 2001-12-05 PT PT01985368T patent/PT1341526E/pt unknown
- 2001-12-05 PL PL362247A patent/PL209703B1/pl unknown
- 2001-12-05 NZ NZ526196A patent/NZ526196A/en not_active IP Right Cessation
- 2001-12-05 BR BR0115965-8A patent/BR0115965A/pt not_active IP Right Cessation
- 2001-12-05 CZ CZ2003-1566A patent/CZ305418B6/cs not_active IP Right Cessation
- 2001-12-05 AT AT01985368T patent/ATE513541T1/de active
- 2001-12-05 SK SK688-2003A patent/SK287613B6/sk not_active IP Right Cessation
- 2001-12-05 HU HU0302319A patent/HU230632B1/hu not_active IP Right Cessation
- 2001-12-05 WO PCT/EP2001/014294 patent/WO2002045754A2/en not_active Ceased
- 2001-12-05 EP EP01985368A patent/EP1341526B1/en not_active Expired - Lifetime
- 2001-12-05 DK DK01985368.8T patent/DK1341526T3/da active
- 2001-12-05 AU AU2002234547A patent/AU2002234547B2/en not_active Ceased
- 2001-12-05 SI SI200130999T patent/SI1341526T1/sl unknown
- 2001-12-05 KR KR1020037007098A patent/KR100847695B1/ko not_active Expired - Fee Related
- 2001-12-05 AU AU3454702A patent/AU3454702A/xx active Pending
- 2001-12-05 ES ES01985368T patent/ES2367009T3/es not_active Expired - Lifetime
- 2001-12-05 CN CNB018201423A patent/CN1304048C/zh not_active Expired - Fee Related
- 2001-12-05 JP JP2002547536A patent/JP4898078B2/ja not_active Expired - Fee Related
- 2001-12-05 RU RU2003119545/15A patent/RU2287999C2/ru not_active IP Right Cessation
- 2001-12-05 IL IL15599201A patent/IL155992A0/xx active IP Right Grant
- 2001-12-05 BR BRPI0115965-8A patent/BRPI0115965B1/pt unknown
- 2001-12-05 CA CA2436599A patent/CA2436599C/en not_active Expired - Fee Related
- 2001-12-05 MX MXPA03005096A patent/MXPA03005096A/es active IP Right Grant
2003
- 2003-05-19 IL IL155992A patent/IL155992A/en not_active IP Right Cessation
- 2003-06-02 ZA ZA200304295A patent/ZA200304295B/en unknown
- 2003-06-03 NO NO20032511A patent/NO332936B1/no not_active IP Right Cessation
- 2003-06-04 EC EC2003004639A patent/ECSP034639A/es unknown
2009
- 2009-04-13 JP JP2009097262A patent/JP2009185052A/ja not_active Withdrawn
2011
- 2011-08-09 CY CY20111100759T patent/CY1112562T1/el unknown

Also Published As

Publication number	Publication date
JP2009185052A (ja)	2009-08-20
DK1341526T3 (da)	2011-10-03
RU2287999C2 (ru)	2006-11-27
CY1112562T1 (el)	2016-02-10
CZ20031566A3 (cs)	2003-09-17
AU2002234547B2 (en)	2005-03-24
ZA200304295B (en)	2004-05-10
SK6882003A3 (en)	2004-01-08
JP4898078B2 (ja)	2012-03-14
KR20040018309A (ko)	2004-03-03
SI1341526T1 (sl)	2011-10-28
EP1341526A2 (en)	2003-09-10
HK1059565A1 (en)	2004-07-09
ECSP034639A (es)	2003-07-25
CN1479612A (zh)	2004-03-03
US7049283B2 (en)	2006-05-23
PL362247A1 (en)	2004-10-18
WO2002045754A2 (en)	2002-06-13
CN1304048C (zh)	2007-03-14
IL155992A (en)	2008-04-13
CZ305418B6 (cs)	2015-09-09
KR100847695B1 (ko)	2008-07-23
ATE513541T1 (de)	2011-07-15
US20020123459A1 (en)	2002-09-05
NO332936B1 (no)	2013-02-04
BR0115965A (pt)	2003-10-28
HUP0302319A2 (hu)	2003-11-28
EP1341526B1 (en)	2011-06-22
NZ526196A (en)	2005-01-28
ES2367009T3 (es)	2011-10-27
HU230632B1 (hu)	2017-05-29
MXPA03005096A (es)	2003-09-05
NO20032511D0 (no)	2003-06-03
AU3454702A (en)	2002-06-18
SK287613B6 (sk)	2011-04-05
CA2436599C (en)	2011-01-25
PL209703B1 (pl)	2011-10-31
IL155992A0 (en)	2003-12-23
PT1341526E (pt)	2011-09-01
JP2004515480A (ja)	2004-05-27
CA2436599A1 (en)	2002-06-13
BRPI0115965B1 (pt)	2017-09-26
WO2002045754A3 (en)	2003-01-03
HUP0302319A3 (en)	2013-04-29

Legal Events

Date	Code	Title	Description
2018-07-23	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO20032511D0 (no)	2003-06-03	Farmasöytiske sammensetninger for oral tilförsel av farmakologisk aktive midler
ITMI20001173A0 (it)	2000-05-26	Composizioni farmaceutiche a rilascio prolungato per la somministrazione parenterale di sostanze idrofile biologicamente attiva.
PL1651248T3 (pl)	2010-02-26	Doustnie dawkowana kompozycja farmaceutyczna zawierająca środek dostarczający w postaci mikronizowanej
ID27504A (id)	2001-04-12	Formulasi oral baru
ATE235895T1 (de)	2003-04-15	Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
BR9801989A (pt)	2000-02-08	Pellets entéricos de fluoxetina.
MXPA02003321A (es)	2004-09-10	Composiciones de liberacion controlada que comprenden nimesulida.
NO20011721D0 (no)	2001-04-05	N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
PT994710E (pt)	2003-02-28	Composicoes farmaceuticas administraveis por via oral incluindo uma benzidrilpiperazina e uma ciclodextrina
CY1111698T1 (el)	2015-10-07	Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
SE0101932D0 (sv)	2001-05-31	Pharmaceutical combinations
ATE252377T1 (de)	2003-11-15	Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
IL157540A0 (en)	2004-03-28	N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
BR0112847A (pt)	2003-06-24	Uso de uma forma de dosagem sólida
WO2003041656A3 (en)	2003-10-23	Soluble drug extended release system
BR0114395A (pt)	2005-08-16	Composição farmacêutica para administração por suprimento via oral
ATE297760T1 (de)	2005-07-15	Pharmazeutische zusammensetzungen enthaltend terbinafin
WO2007011958A3 (en)	2007-04-12	Intraoral dosage forms of glucagon
TR200601092T1 (tr)	2006-08-21	İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
MXPA01008348A (es)	2004-03-19	Microcapsulas para la liberacion prolongada de farmacos.
DE69904020D1 (de)	2003-01-02	Pharmazeutische zusammensetzung zur nasalen verabreichung von thiocolchicosid
AU2502301A (en)	2001-06-04	Medicament and combination of compatible medicaments
DK1499278T3 (da)	2005-10-03	Farmaceutisk doseringsform, som udviser umiddelbar frigivelse, og som omfatter polymorf tibolon
HRP20070081T5 (hr)	2007-08-31	Nazalni farmaceutski pripravak piribedila
PA8531801A1 (es)	2003-11-12	Formulaciones estabilizadas que comprenden composiciones hidroliticamente inestables